BioNTech SE

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BioNTech SE and other ETFs, options, and stocks.

About BNTX

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. 

CEO
Ugur Sahin
CEOUgur Sahin
Employees
7,807
Employees7,807
Headquarters
Mainz, Rheinland-Pfalz
HeadquartersMainz, Rheinland-Pfalz
Founded
2008
Founded2008
Employees
7,807
Employees7,807

BNTX Key Statistics

Market cap
23.82B
Market cap23.82B
Price-Earnings ratio
-16.03
Price-Earnings ratio-16.03
Dividend yield
Dividend yield
Average volume
945.18K
Average volume945.18K
High today
$95.99
High today$95.99
Low today
$92.50
Low today$92.50
Open price
$93.38
Open price$93.38
Volume
1.04M
Volume1.04M
52 Week high
$124.00
52 Week high$124.00
52 Week low
$79.52
52 Week low$79.52

BNTX News

TipRanks 3d
BioNTech Launches $1 Billion ADS Buyback to Support Long-Term Growth Strategy

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 5d
Assessing BioNTech (NasdaqGS:BNTX) Valuation After Weak Quarter And Lower 2026 Guidance

Advertisement BioNTech's weak quarter and rising uncertainty BioNTech (BNTX) reported first quarter sales of €118.1 million and a net loss of €531.9 million,...

Assessing BioNTech (NasdaqGS:BNTX) Valuation After Weak Quarter And Lower 2026 Guidance
Benzinga 5d
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

The stock’s decline comes amid a broader market rally, with major indices like the Nasdaq up by 1.19% and the S&P 500 gaining 0.72%. • BioNTech stock is under...

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

Analyst ratings

76%

of 21 ratings
Buy
76.2%
Hold
19%
Sell
4.8%

More BNTX News

Nasdaq 6d
BioNTech Q1 Net Loss Widens; Backs FY26 Revenue Outlook

(RTTNews) - Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Tuesday a net loss of 531.9 million euros or 2.10 euros per...

BioNTech Q1 Net Loss Widens; Backs FY26 Revenue Outlook
TipRanks 6d
BioNTech reports Q1 adjusted EPS vs.

Reports Q1 EUR118.1M vs. EUR182.8M last year. “In the Q1, we made substantial progress in executing towards our oncology strategy, highlighted by data presentat...

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.